09.23.2026
Aurion Biotech Completes Enrollment in Phase 3 ASTRA Trial of AURN001 for Corneal Edema
Aurion Biotech has completed patient enrollment in the US phase 3 ASTRA pivotal study evaluating AURN001, an investigational regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction, the company announced. AURN001 is a single-administration combination therapy consisting of unmodified human corneal endothelial cells (neltependocel) and the rho-kinase inhibitor Y-27632.